Detalhe da pesquisa
1.
Dose escalation of biologic treatment in patients with moderate-to-severe psoriasis in Japan.
Exp Dermatol
; 33(5): e15067, 2024 May.
Artigo
Inglês
| MEDLINE | ID: mdl-38757460
2.
Bimekizumab efficacy and safety in patients with moderate-to-severe plaque psoriasis who switched from adalimumab, ustekinumab or secukinumab: results from phase III/IIIb trials.
Br J Dermatol
; 188(3): 330-340, 2023 02 22.
Artigo
Inglês
| MEDLINE | ID: mdl-36751950
3.
Bimekizumab efficacy and safety in patients with moderate to severe plaque psoriasis: Two-year interim results from the open-label extension of the randomized BE RADIANT phase 3b trial.
J Am Acad Dermatol
; 89(3): 486-495, 2023 09.
Artigo
Inglês
| MEDLINE | ID: mdl-37182701
4.
PsoBarrier EU study: a Multicentre, Cross-sectional Survey Investigating the Quality of Psoriasis Care in Four European Countries.
Acta Derm Venereol
; 103: adv6532, 2023 Aug 31.
Artigo
Inglês
| MEDLINE | ID: mdl-37649411
5.
Quality of life and stigmatization in people with skin diseases in Europe: A large survey from the 'burden of skin diseases' EADV project.
J Eur Acad Dermatol Venereol
; 37 Suppl 7: 6-14, 2023 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-37806002
6.
Public perception of dermatologists in Europe: Results from a population-based survey.
J Eur Acad Dermatol Venereol
; 37 Suppl 7: 27-37, 2023 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-37806001
7.
The journey of patients with skin diseases from the first consultation to the diagnosis in a representative sample of the European general population from the EADV burden of skin diseases study.
J Eur Acad Dermatol Venereol
; 37 Suppl 7: 17-24, 2023 Oct.
Artigo
Inglês
| MEDLINE | ID: mdl-37806003
8.
Tyk2 Targeting in Immune-Mediated Inflammatory Diseases.
Int J Mol Sci
; 24(4)2023 Feb 08.
Artigo
Inglês
| MEDLINE | ID: mdl-36834806
9.
Consistent safety profile with up to 5 years of continuous treatment with guselkumab: Pooled analyses from the phase 3 VOYAGE 1 and VOYAGE 2 trials of patients with moderate-to-severe psoriasis.
J Am Acad Dermatol
; 86(4): 827-834, 2022 04.
Artigo
Inglês
| MEDLINE | ID: mdl-34798201
10.
Comparative effectiveness of biologics in clinical practice: week 12 primary outcomes from an international observational psoriasis study of health outcomes (PSoHO).
J Eur Acad Dermatol Venereol
; 36(11): 2087-2100, 2022 Nov.
Artigo
Inglês
| MEDLINE | ID: mdl-35766124
11.
Factors associated with adverse COVID-19 outcomes in patients with psoriasis-insights from a global registry-based study.
J Allergy Clin Immunol
; 147(1): 60-71, 2021 01.
Artigo
Inglês
| MEDLINE | ID: mdl-33075408
12.
IL-1 Family Cytokines in Inflammatory Dermatoses: Pathogenetic Role and Potential Therapeutic Implications.
Int J Mol Sci
; 23(16)2022 Aug 22.
Artigo
Inglês
| MEDLINE | ID: mdl-36012744
13.
LRP1/CD91 is highly expressed in monocytes from patients with vitiligo - even after repigmentation.
Exp Dermatol
; 30(3): 390-395, 2021 03.
Artigo
Inglês
| MEDLINE | ID: mdl-33249636
14.
Long-term efficacy and safety of brodalumab in the treatment of psoriasis: 120-week results from the randomized, double-blind, placebo- and active comparator-controlled phase 3 AMAGINE-2 trial.
J Am Acad Dermatol
; 82(2): 352-359, 2020 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-31175909
15.
The Role of Epithelial-to-Mesenchymal Transition in Cutaneous Squamous Cell Carcinoma : Epithelial-to-Mesenchymal Transition in Cutaneous SCC.
Curr Treat Options Oncol
; 21(6): 47, 2020 04 30.
Artigo
Inglês
| MEDLINE | ID: mdl-32350682
16.
Good response to pulsed dye laser in patients with capillary malformation-arteriovenous malformation syndrome (CM-AVM).
Pediatr Dermatol
; 37(2): 342-344, 2020 Mar.
Artigo
Inglês
| MEDLINE | ID: mdl-31944370
17.
Psoriasis precipitated by timolol eye drops. A series of eight cases.
Australas J Dermatol
; 61(1): e91-e93, 2020 Feb.
Artigo
Inglês
| MEDLINE | ID: mdl-31489616
18.
Clinical and genetic differences between pustular psoriasis subtypes.
J Allergy Clin Immunol
; 143(3): 1021-1026, 2019 03.
Artigo
Inglês
| MEDLINE | ID: mdl-30036598
19.
Absolute and Relative Psoriasis Area and Severity Indices (PASI) for Comparison of the Efficacy of Ixekizumab to Etanercept and Placebo in Patients with Moderate-to-severe Plaque Psoriasis: An Integrated Analysis of UNCOVER-2 and UNCOVER-3 Outcomes.
Acta Derm Venereol
; 99(11): 971-977, 2019 Oct 01.
Artigo
Inglês
| MEDLINE | ID: mdl-31240322
20.
Best-practice Indicators in Psoriatic Disease Care.
J Rheumatol Suppl
; 95: 38-45, 2019 Jun.
Artigo
Inglês
| MEDLINE | ID: mdl-31154403